Skip to Content
Merck
CN

920444

mPEG functionalized gelatin

50% PEGylation, PEG average Mn 1k, gel strength 300 g Bloom

Synonym(s):

PEGylated Gelatin, Gelatin / GelMA & derivatives

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Linear Formula:
(C32H50N9O12-)m(CH2CH2O)n
NACRES:
NA.23
UNSPSC Code:
12352201
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Level

form

(solid or chunk(s) or fiber)

mol wt

PEG average Mn 1k

color

white to off-white

storage temp.

2-8°C

Application

mPEG functionalized gelatin is Type A gelatin grafted with PEG that can be used in drug delivery research. Gelatin is a denatured protein that is obtained by hydrolysis of animal collagen. Its biodegradability, biocompatibility, chemical modification potential and cross-linking possibility make gelatin-based nanoparticles (GNPs) a promising carrier system for drug delivery applications. mPEG functionalization has several advantages − prolonged circulation in the body, decreased degradation by metabolic enzymes, and reduction or elimination of protein immunogencity.


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

动物来源培养基

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



A novel smart PEGylated gelatin nanoparticle for co-delivery of doxorubicin and betanin: A strategy for enhancing the therapeutic efficacy of chemotherapy.
Ghorbani M, et al.
Materials Science and Engineering, C, 97, 833-841 (2019)
Modified gelatin nanoparticles for gene delivery.
Wettig S D, et al.
Int. J. Pharmacol., 554, 224-234 (2019)
Sajed Amjadi et al.
Materials science & engineering. C, Materials for biological applications, 97, 833-841 (2019-01-27)
Betanin (BET) can reduce the side effects of potent anticancer drugs e.g. doxorubicin (DOX) on the normal tissues in co-administration with them because of the synergistic therapeutic effect and consequently the reduced required amount of anticancer agents. Despite interest in



Global Trade Item Number

SKUGTIN
920444-1G04065266006520